Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization

Following the FDA-approval of the hematopoietic stem cell (HSC) mobilizer plerixafor, orally available and potent CXCR4 antagonists were pursued. One such proposition was AMD11070, which was orally active and had superior antagonism in vitro; however, it did not appear as effective for HSC mobilizat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Commun Biol
Autors principals: Jørgensen, Astrid S., Daugvilaite, Viktorija, De Filippo, Katia, Berg, Christian, Mavri, Masa, Benned-Jensen, Tau, Juzenaite, Goda, Hjortø, Gertrud, Rankin, Sara, Våbenø, Jon, Rosenkilde, Mette M.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8115334/
https://ncbi.nlm.nih.gov/pubmed/33980979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s42003-021-02070-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars